Vasomune Therapeutics has been working with University of Iowa Pharmaceuticals (UIP) through a strategic partnership toward the manufacture of AV-001, a biopharmaceutical therapeutic that treats acute respiratory distress syndrome (ARDS) emanating from the novel coronavirus, COVID-19 – click here to learn more.